相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Improved Anticancer Effect of Recombinant Protein izTRAIL Combined with Sorafenib and Peptide iRGD
Roman Fadeev et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
Naiqing Ding et al.
NATURE COMMUNICATIONS (2019)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Z. Wu et al.
PHARMACOLOGY & THERAPEUTICS (2018)
A Critical need for Better Cancer Immunotherapy Models: Are Organotypic Tumor spheroid Cultures the Answer?
Justin M. Balko et al.
CANCER DISCOVERY (2018)
T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy
Robert Sackstein et al.
LABORATORY INVESTIGATION (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells
Chien-Hsing Chang et al.
CANCER RESEARCH (2017)
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2016)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan et al.
SCIENCE (2016)
Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells
Prashant Hiwarkar et al.
BLOOD (2015)
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
Takuya Osada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Bispecific antibodies
Roland E. Kontermann et al.
DRUG DISCOVERY TODAY (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells
Teemu T. Junttila et al.
CANCER RESEARCH (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
Tumor targeting via integrin ligands
Udaya Kiran Marelli et al.
FRONTIERS IN ONCOLOGY (2013)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Kazuki N. Sugahara et al.
SCIENCE (2010)
Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
Kazuki N. Sugahara et al.
CANCER CELL (2009)
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration
Tambet Teesalu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
K Brischwein et al.
MOLECULAR IMMUNOLOGY (2006)
分享论文
